Product Description
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Insomnia|Stress Disorders, Post-Traumatic
Phase 1: Bipolar Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00907985 | P1 |
Terminated |
Bipolar Disorder |
2010-06-10 |
|
06-M-0253 | P2 |
Completed |
Stress Disorders, Post-Traumatic |
2009-06-01 |
|
2007-004035-35 | P2 |
Completed |
Insomnia |
2008-05-07 |
|
NKI110334 | P2 |
Completed |
Insomnia |
2008-05-07 |